Tremfya Market

Tremfya Market Forecast and Outlook 2025 to 2035

The global Tremfya market is projected to reach USD 8.6 billion by 2035, recording an absolute increase of USD 4.54 billion over the forecast period. The market is valued at USD 4.06 billion in 2025 and is set to rise at a CAGR of 7.8% during the assessment period.

Quick Stats for Tremfya Market

• Tremfya Market Value (2025): USD 4.06 billion
• Tremfya Market Forecast Value (2035): USD 8.6 billion
• Tremfya Market Forecast CAGR: 7.8%
• Leading Application in Tremfya Market: Plaque Psoriasis (87.0%)
• Key Growth Regions in Tremfya Market: Asia Pacific, Latin America, and Middle East & Africa
• Top Players in Tremfya Market: Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, Eli Lilly & Company, UCB S.A., Amgen Inc., Bristol Myers Squibb, Sun Pharma, Biocon Biologics, MorphoSys AG

The overall market size is expected to grow by approximately 2.1 times during the same period, supported by expanding biologics adoption for moderate-to-severe plaque psoriasis and rising recognition of IL-23 pathway inhibition advantages across dermatology and rheumatology applications, driving demand for long-acting targeted therapies and increasing investments in patient access programs with improved dosing convenience across chronic inflammatory conditions globally.

Patients seek sustained disease control while minimizing treatment burden and safety concerns, with Tremfya (guselkumab) providing documented clinical benefits including superior skin clearance rates, extended dosing intervals, and favorable safety profiles compared to conventional systemic therapies alone.

Rising preference for targeted biologic therapies and expanding reimbursement coverage enabling broader patient access create substantial opportunities for healthcare providers and pharmaceutical partners. However, biosimilar competition and high treatment costs may pose obstacles to market penetration in price-sensitive regions.

The plaque psoriasis segment dominates market activity, driven by extensive clinical evidence supporting guselkumab's efficacy in achieving complete or near-complete skin clearance and proven long-term disease control across diverse patient populations worldwide.

Dermatologists increasingly recognize the therapeutic advantages of IL-23 inhibition, with typical treatment protocols providing durable response maintenance and favorable dosing schedules at eight-week intervals following initial loading doses through established specialty pharmacy networks.

The psoriatic arthritis segment demonstrates robust growth potential, supported by expanding label indications and clinical validation in musculoskeletal manifestations requiring dual efficacy in skin and joint symptoms. Hospital pharmacies emerge as the dominant distribution channel, reflecting specialty medication handling requirements and reimbursement processes in tertiary care settings. North America represents the leading regional market, driven by established biologics adoption patterns and comprehensive insurance coverage supporting high-cost specialty pharmaceuticals.

Regional dynamics show North America maintaining overwhelming market dominance, supported by advanced healthcare infrastructure and established specialty dermatology practices across integrated healthcare systems. Asia Pacific demonstrates the fastest growth trajectory driven by improving reimbursement accessibility and expanding specialty care infrastructure in emerging economies implementing modern biologics treatment protocols, while Europe emphasizes evidence-based prescribing and cost-effectiveness evaluation.

USA leads country-level consumption through extensive biologics utilization and direct-to-consumer marketing supporting patient awareness, followed by China and India experiencing rapid market development supported by healthcare modernization and rising chronic disease management priorities.

The competitive landscape features moderate concentration with Johnson & Johnson (Janssen) maintaining market leadership position as Tremfya's originator, while established biopharmaceutical companies including AbbVie Inc., Novartis AG, and Eli Lilly & Company compete through alternative IL-23 inhibitors and competing biologic mechanisms across psoriasis treatment paradigms.

Tremfya Market Year-over-Year Forecast 2025 to 2035

Between 2025 and 2029, the Tremfya market is projected to expand from USD 4.06 billion to USD 5.47 billion, resulting in a value increase of USD 1.41 billion, which represents 31.1% of the total forecast growth for the period. This phase of development will be shaped by rising demand for extended dosing interval biologics addressing patient convenience and treatment adherence challenges, label expansion into additional inflammatory indications including Crohn's disease and ulcerative colitis under clinical investigation, as well as expanding patient access programs and specialty pharmacy partnerships. Companies are establishing competitive positions through investment in real-world evidence generation, patient support services with injection training and financial assistance, and strategic market expansion across hospital networks, academic medical centers, and integrated dermatology practices.

From 2029 to 2035, the market is forecast to grow from USD 5.47 billion to USD 8.6 billion, adding another USD 3.13 billion, which constitutes 68.9% of the overall expansion. This period is expected to be characterized by the expansion of specialized treatment applications, including pediatric psoriasis formulations and combination therapy regimens with complementary mechanisms tailored for refractory patient populations, strategic collaborations between Janssen and healthcare systems implementing value-based contracting arrangements, and an enhanced focus on long-term safety validation and comparative effectiveness research. The growing emphasis on personalized medicine approaches and rising adoption of biomarker-guided therapy selection with predictive response indicators will drive demand for targeted IL-23 inhibition across diverse patient phenotypes and treatment-resistant disease manifestations.

Tremfya Market Key Takeaways

Metric	Value
Market Value (2025)	USD 4.06 billion
Market Forecast Value (2035)	USD 8.6 billion
Forecast CAGR (2025-2035)	7.8%

Why is the Tremfya Market Growing?

The Tremfya market grows by enabling patients with moderate-to-severe plaque psoriasis to achieve sustained disease remission and improve quality of life while addressing treatment burden and safety concerns without compromising long-term efficacy or tolerability.

Patients face mounting pressure to maintain skin clearance and prevent disease relapse while managing injection frequency and potential adverse effects across extended treatment durations, with Tremfya (guselkumab) typically providing selective IL-23 inhibition, convenient eight-week maintenance dosing, and favorable cardiovascular safety profiles compared to alternative biologic agents alone, making targeted pathway inhibition essential for optimized chronic disease management.

The dermatology specialty's need for efficacious and convenient biologic therapies creates demand for specialized IL-23 inhibitors that can provide superior clinical outcomes, enhance patient adherence, and support long-term disease control without requiring frequent healthcare visits or intensive monitoring protocols.

Dermatologist adoption and clinical guideline recommendations drive utilization in academic medical centers, community dermatology practices, and integrated healthcare systems, where treatment efficacy has direct impact on patient satisfaction and healthcare resource utilization.

The increasing prevalence of moderate-to-severe psoriasis globally, affecting approximately 2-3% of populations with substantial disease burden, creates expanding patient populations requiring advanced biologic interventions.

Rising awareness about psoriatic comorbidities including cardiovascular disease and metabolic syndrome enables holistic treatment approaches. However, high medication costs and prior authorization requirements may limit treatment access and affect market penetration among underinsured patient populations with financial barriers.

Segmental Analysis

The market is segmented by application, distribution channel, and region. By application, the market is divided into plaque psoriasis, psoriatic arthritis, and others. Plaque psoriasis is further categorized into moderate-to-severe plaque psoriasis, chronic plaque psoriasis, and difficult-to-treat areas. Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies include large hospitals and specialty centers, tertiary care hospitals, and government hospitals. Regionally, the market is divided into Asia Pacific, Europe, North America, Latin America, and Middle East & Africa.

By Application, Which Segment Accounts for the Dominant Market Share?

The plaque psoriasis segment represents the dominant force in the Tremfya market, capturing 87.0% of total market share in 2025. This established indication category encompasses solutions featuring FDA-approved and EMA-authorized utilization for moderate-to-severe disease presentations, including advanced treatment protocols targeting complete skin clearance (PASI 100) and sustained remission maintenance through selective IL-23p19 subunit inhibition that enables superior clinical outcomes and reduced relapse rates across diverse plaque psoriasis phenotypes worldwide.

The plaque psoriasis segment's market leadership stems from its extensive clinical evidence base, with solutions capable of addressing refractory disease inadequately controlled by conventional systemics including methotrexate and cyclosporine, while maintaining excellent long-term safety profiles and convenient dosing schedules across adult patient populations.

The psoriatic arthritis segment maintains meaningful market share in the 10-12% range, serving patients requiring dual efficacy addressing both cutaneous and musculoskeletal manifestations where joint inflammation, enthesitis, and dactylitis accompany skin disease requiring comprehensive disease-modifying treatment approaches.

These solutions offer validated efficacy in preventing structural joint damage and improving physical function while providing adequate skin clearance to support holistic disease management. The psoriatic arthritis segment demonstrates strong growth potential, driven by label expansion and increasing recognition of IL-23's role in inflammatory arthritis pathogenesis.

Within the plaque psoriasis category, moderate-to-severe presentations demonstrate dominant utilization, driven by regulatory approval criteria and clinical trial enrollment definitions requiring minimum disease severity thresholds. This subsegment benefits from established treatment algorithms and dermatologist familiarity with biologic prescribing protocols.

Key therapeutic advantages driving the plaque psoriasis segment include:

• Advanced IL-23 pathway selectivity characteristics with targeted p19 subunit inhibition enabling superior specificity and reduced off-target effects across immune pathways
• Established dosing convenience allowing eight-week maintenance intervals and subcutaneous self-administration without requiring healthcare facility visits for treatment delivery
• Enhanced durability features enabling sustained disease remission and reduced relapse rates during treatment interruptions while maintaining clinical response consistency
• Superior safety profile providing favorable cardiovascular outcomes and infection risk profiles for patients with metabolic comorbidities across long-term treatment exposure

By Distribution Channel, Which Segment Accounts for the Largest Market Share?

Hospital pharmacies dominate the Tremfya distribution channel landscape with approximately 51.2% market share in 2025, reflecting the critical role of specialty medication infrastructure in supporting biologic dispensing and reimbursement processing across integrated healthcare delivery systems worldwide.

The hospital pharmacies segment's market leadership is reinforced by payer requirements for specialty pharmacy utilization, comprehensive patient counseling services, and prior authorization management supporting treatment initiation and continuation across complex reimbursement environments.

Within this segment, large hospitals and specialty centers represent the primary distribution setting, driven by their concentration of dermatology and rheumatology specialists prescribing biologic therapies and integrated specialty pharmacy operations. This subsegment benefits from comprehensive patient support services and coordinated care delivery models.

The retail pharmacies segment represents an important distribution category, demonstrating steady presence through specialized retail specialty pharmacy networks including CVS Specialty, Walgreens Specialty Pharmacy, and independent specialty providers requiring temperature-controlled storage and patient education capabilities. This segment benefits from convenience for stable patients and established community pharmacy relationships.

The online pharmacies segment maintains growing presence through mail-order specialty pharmacy services and direct-to-patient home delivery models, while digital pharmacy platforms serve tech-savvy patient populations preferring convenient medication access and automated refill management.

Key market dynamics supporting distribution channel growth include:

• Hospital pharmacy expansion driven by integrated delivery networks and accountable care organizations, requiring comprehensive specialty medication management
• Retail specialty pharmacy modernization trends require patient education capabilities and reimbursement expertise
• Integration of patient support programs enabling financial assistance coordination and injection training services
• Growing emphasis on adherence monitoring and outcomes tracking driving specialty pharmacy value-added services without compromising patient privacy

What are the Drivers, Restraints, and Key Trends of the Tremfya Market?

The market is driven by three concrete demand factors tied to clinical outcomes and patient convenience. First, rising biologics adoption for moderate-to-severe psoriasis and shifting treatment paradigms toward earlier biologic intervention create expanding patient populations eligible for IL-23 inhibitors, with dermatologists implementing targeted therapies that provide superior efficacy compared to conventional systemics, requiring specialty medication access. Second, growing clinical evidence demonstrating Tremfya's superior durability and extended dosing intervals drive physician preference, with numerous comparative effectiveness studies showing significant advantages in sustained disease control and patient adherence through convenient maintenance regimens by 2030. Third, increasing label expansions and indication approvals for psoriatic arthritis and investigational inflammatory bowel disease applications enable broader market opportunities that improve revenue potential while addressing unmet medical needs through validated therapeutic mechanisms.

Market restraints include high medication costs and reimbursement challenges that can limit patient access and create financial barriers, particularly in markets where specialty biologic coverage requires extensive prior authorization documentation and step therapy requirements prove burdensome. Biosimilar competition and patent expiration considerations pose another significant obstacle, as regulatory pathways for IL-23 inhibitor biosimilars develop, potentially affecting pricing power and market share retention during loss of exclusivity periods. Safety monitoring requirements and rare adverse event concerns including serious infections and malignancy risks create additional prescribing hesitancy, demanding comprehensive patient selection and ongoing surveillance protocols.

Key trends indicate accelerated personalized medicine adoption in developed markets, particularly USA and Europe, where biomarker research demonstrates potential to predict treatment response and optimize therapy selection. Combination therapy trends toward integrating biologics with phototherapy or conventional systemics enable enhanced efficacy that addresses refractory disease through complementary mechanisms and synergistic effects. However, the market thesis could face disruption if significant advances in oral small molecule therapies or major shifts in treatment guidelines toward alternative biologic mechanisms reduce reliance on IL-23 inhibition as preferred therapeutic approach.

Analysis of the Tremfya Market by Key Countries

Country	CAGR (2025-2035)
India	9.1%
China	8.5%
USA	7.9%
Germany	6.8%
Saudi Arabia	6.5%
Japan	6.2%
Brazil	5.4%

The global Tremfya market is expanding steadily, with India leading at a 9.1% CAGR through 2035, driven by rapid diagnosis growth, improved specialty care access, and rising awareness about advanced psoriasis treatments. China follows at 8.5%, supported by fastest Asia Pacific expansion, increased reimbursement coverage, and tier-2 and tier-3 city healthcare access improvements.

USA records 7.9%, reflecting high biologics adoption patterns, strong IL-23 inhibitor uptake, and broad reimbursement infrastructure. Germany advances at 6.8%, leveraging stable biologics usage and specialist-driven dermatology demand. Saudi Arabia posts 6.5%, focusing on Vision 2030 healthcare expansion and chronic disease management enhancement, while Japan grows at 6.2%, emphasizing aging population needs and hospital-based biologics prescribing expansion. Brazil demonstrates 5.4% growth, anchored by improving public health procurement of biologic medications.

How is India Leading Global Market Expansion?

India demonstrates the strongest growth potential in the Tremfya market with a CAGR of 9.1% through 2035. The country's leadership position stems from rapidly improving psoriasis diagnosis rates, expanding dermatology specialty care infrastructure, and rising awareness about biologic treatment options driving adoption of advanced therapies. Growth is concentrated in major metropolitan areas and tier-1 cities, including Mumbai, Delhi, Bangalore, and Hyderabad, where patients are increasingly accessing specialty dermatology clinics and academic medical centers offering biologic prescribing expertise beyond traditional systemic therapy approaches.

Distribution channels through hospital pharmacies, specialty pharmacy networks, and patient assistance programs expand product accessibility across urban patient populations with insurance coverage or out-of-pocket payment capacity. The country's growing medical tourism sector and international standard healthcare facilities provide strong momentum for premium biologic adoption, including comprehensive deployment across affluent patient segments seeking best-in-class psoriasis management.

Key market factors:

• Urban patient populations concentrated in metropolitan areas with access to board-certified dermatologists and rheumatology specialists
• Healthcare infrastructure expansion through corporate hospital chains and specialty clinics implementing biologic treatment protocols
• Comprehensive patient assistance programs, including manufacturer-sponsored financial support with proven access enhancement
• Specialty pharmacy development featuring temperature-controlled storage and patient counseling capabilities for biologic medication handling

Why is China Emerging as a High-Growth Market?

In major urban centers including Beijing, Shanghai, Shenzhen, and Guangzhou, the adoption of biologic therapies for psoriasis is accelerating across specialty hospitals, driven by improving reimbursement policies and expanding healthcare infrastructure. The market demonstrates strong growth momentum with a CAGR of 8.5% through 2035, linked to comprehensive healthcare modernization and increasing recognition of psoriasis as significant quality of life burden requiring advanced treatment.

Chinese patients are implementing modern treatment protocols with IL-23 inhibitors to achieve superior disease control while meeting growing expectations for Western-standard medical care. The country's expanding tier-2 and tier-3 city healthcare capabilities create ongoing demand for specialty medications, while increasing domestic pharmaceutical partnerships enable local manufacturing and distribution optimization.

Key development areas:

• Hospital-based dermatology leading biologic adoption with emphasis on academic medical centers and tertiary care facilities
• Reimbursement expansion through national and provincial insurance programs increasing patient affordability
• Healthcare access improvement enabling specialty care availability beyond first-tier cities through telemedicine consultation
• Growing preference for innovative biologics alongside traditional Chinese medicine integration supporting holistic disease management

What drives USA’s Market Resilience?

USA’s market expansion is driven by diverse prescribing patterns, including established dermatology specialist adoption and direct-to-consumer marketing supporting patient treatment requests. The country demonstrates solid growth potential with a CAGR of 7.9% through 2035, supported by comprehensive insurance coverage for specialty biologics and ongoing clinical research validating treatment approaches.

American patients face mature biologic utilization environment with multiple IL-23 inhibitor options available, requiring differentiation through clinical evidence, convenience features, and patient support programs. However, established specialty pharmacy infrastructure and high-value healthcare spending create stable baseline demand for premium biologics, particularly among commercially insured patients and Medicare beneficiaries where specialty medication benefits support treatment access.

Market characteristics:

• Dermatology specialists showing robust biologic prescribing with substantial patient volume across diverse practice settings
• Regional preferences varying between academic medical center concentration in research markets and community dermatology adoption in commercial insurance areas
• Future projections indicate continued market growth with emphasis on comparative effectiveness research and value-based contracting
• Growing emphasis on patient preference studies and quality of life outcomes supporting shared decision-making and treatment selection

How does Germany Demonstrate Evidence-Based Treatment Leadership?

The German market leads in systematic biologic evaluation based on integration with health technology assessment and guideline-driven prescribing protocols for optimal therapeutic value. The country shows solid potential with a CAGR of 6.8% through 2035, driven by comprehensive dermatology specialist networks and evidence-based medicine culture in major clinical regions, including Bavaria, North Rhine-Westphalia, Baden-Württemberg, and Hesse.

German dermatologists are adopting IL-23 inhibitors through structured treatment algorithms and national psoriasis registries for long-term safety monitoring, particularly in university hospitals and office-based specialists maintaining rigorous prescribing standards. Distribution channels through hospital pharmacies and specialized pharmaceutical wholesalers expand coverage across integrated healthcare delivery systems.

Leading market segments:

• Academic dermatology centers implementing comprehensive biologic treatment programs with research participation
• Evidence-based prescribing through adherence to S3 treatment guidelines and consensus recommendations
• Strategic registry participation between prescribers and pharmaceutical manufacturers expanding real-world evidence generation
• Focus on cost-effectiveness analysis and budget impact considerations addressing healthcare system sustainability

What Positions Saudi Arabia for Healthcare Transformation Growth?

In Riyadh, Jeddah, Dammam, and other major cities, healthcare facilities are implementing advanced biologic therapies through specialty hospitals and private healthcare providers, with documented case series showing substantial patient outcomes improvement through modern psoriasis management protocols. The market shows strong growth potential with a CAGR of 6.5% through 2035, linked to Vision 2030 healthcare transformation initiatives and increasing emphasis on chronic disease management quality.

Healthcare providers are adopting specialty biologics with government support to enhance population health outcomes while maintaining standards expected in modern healthcare systems. The country's substantial healthcare investment creates ongoing opportunities for premium medication access that supports quality improvement and international standard care delivery.

Market development factors:

• Healthcare system transformation leading specialty care expansion with emphasis on chronic disease management
• Insurance coverage development providing growth opportunities in both public and private healthcare sectors
• Strategic healthcare infrastructure investments expanding specialty hospital capacity and pharmaceutical logistics
• Emphasis on medical tourism and international patient care supporting premium treatment availability

How Does Japan Show Specialty Care Integration?

Japan's Tremfya market demonstrates sophisticated healthcare integration focused on hospital-based biologic prescribing and comprehensive patient monitoring across established dermatology networks.

The country maintains steady growth momentum with a CAGR of 6.2% through 2035, driven by aging population needs and preferences for university hospital care that align with Japanese medical culture standards.

Major metropolitan areas, including Tokyo, Osaka, Nagoya, and Fukuoka, showcase advanced biologic utilization where academic medical centers achieve significant patient enrollment through research protocols and specialist referral patterns.

Key market characteristics:

• Hospital-centered care models maintaining dominant biologic prescribing through university and tertiary care facilities
• Aging population demographics driving increased chronic disease prevalence and treatment demand
• Manufacturing partnerships through Japanese pharmaceutical companies and international innovators supporting local market development
• Emphasis on long-term safety monitoring and pharmacovigilance addressing regulatory requirements and clinical practice standards

What Characterizes Brazil's Access Expansion?

Brazil's Tremfya market demonstrates evolving access dynamics focused on public health system procurement and private insurance coverage across diverse socioeconomic populations.

The country maintains moderate growth at a CAGR of 5.4% through 2035, driven by improving biologic availability through SUS (Sistema Único de Saúde) and supplemental health plan coverage expansion. Major metropolitan areas, including São Paulo, Rio de Janeiro, Brasília, and Belo Horizonte, showcase growing biologic access where specialty dermatology clinics and university hospitals provide advanced psoriasis care.

Key market characteristics:

• Public healthcare system leading biologic access expansion through government procurement and specialized pharmacy programs
• Private insurance coverage through supplemental health plans providing growth opportunities for commercially insured populations
• Judicial access routes enabling individual patient access through legal mechanisms addressing treatment denials
• Cost considerations emphasizing generic and biosimilar alternatives alongside innovator biologic positioning

Europe Market Split by Country

The Tremfya market in Europe is projected to grow from USD 0.52 billion in 2025 to USD 1.15 billion by 2035, registering a CAGR of 8.2% over the forecast period. Germany is expected to maintain its leadership position with a 34.0% market share in 2025, adjusting to 33.5% by 2035, supported by its extensive dermatology specialist infrastructure, comprehensive health technology assessment frameworks, and evidence-based prescribing culture serving major European markets.

France follows with a 23.0% share in 2025, projected to reach 23.5% by 2035, driven by comprehensive hospital pharmacy networks and ongoing dermatology treatment protocol development. UK holds a 19.5% share in 2025, expected to maintain 20.0% by 2035 through continued NHS specialty commissioning and NICE guidance implementation.

Italy commands a 13.0% share, while Spain accounts for 8.0% in 2025. The Rest of Europe region is anticipated to gain momentum, expanding its collective share from 2.5% to 3.0% by 2035, attributed to increasing biologic adoption in Nordic countries implementing modern dermatology practices and emerging Eastern European markets developing specialty pharmaceutical access infrastructure.

Competitive Landscape of the Tremfya Market

The Tremfya market features approximately 8-10 meaningful players with moderate concentration, where the top three companies control roughly 40-45% of IL-23 inhibitor and broader psoriasis biologics market share through established product portfolios, extensive clinical development programs, and comprehensive market access strategies. Competition centers on clinical differentiation, dosing convenience, and safety profile advantages rather than price competition alone.

Market leaders include Johnson & Johnson (Janssen) as Tremfya's originator, alongside AbbVie Inc. with competing IL-23 inhibitor Skyrizi (risankizumab), and Novartis AG with alternative biologic mechanisms, which maintain competitive advantages through robust clinical evidence, global commercialization capabilities, and deep expertise in immunology drug development, creating strong physician preference among dermatologists and rheumatologists seeking proven treatment efficacy.

These companies leverage extensive Phase III clinical trial programs and ongoing post-marketing studies demonstrating long-term safety to defend market positions while expanding into additional inflammatory indications including inflammatory bowel disease and hidradenitis suppurativa.

Challengers encompass established biopharmaceutical companies including Eli Lilly & Company, Amgen Inc., and UCB S.A., which compete through alternative IL-17 inhibitors and TNF inhibitors offering differentiated mechanisms, varied dosing schedules, and specific safety considerations. Emerging biosimilar developers, including Sun Pharma, Biocon Biologics, and specialty pharmaceutical companies, focus on developing follow-on biologics as patents expire, offering potential cost savings and expanded access in price-sensitive markets.

Regional pharmaceutical companies and specialty manufacturers create competitive pressure through local market presence and government procurement relationships, particularly in emerging markets including India, China, and Latin America, where affordability considerations influence prescribing decisions and healthcare policy interventions.

Market dynamics favor companies that combine clinical superiority with patient support program comprehensiveness and payer relationship strength that address stakeholder requirements from efficacy validation through reimbursement optimization and adherence support. Strategic emphasis on real-world evidence generation, health economics research demonstrating cost-effectiveness, and patient-reported outcome improvements enables differentiation in increasingly competitive immunology therapeutic areas across developed and emerging pharmaceutical markets globally.

Global Tremfya Market — Stakeholder Contribution Framework

Tremfya represents a critical immunology therapeutic that enables patients with moderate-to-severe plaque psoriasis and psoriatic arthritis to achieve sustained disease remission and improve quality of life while addressing treatment convenience and long-term safety considerations, typically providing selective IL-23 inhibition, extended dosing intervals, and favorable safety profiles compared to alternative biologic mechanisms alone while ensuring durable clinical responses and comprehensive disease control.

With the market projected to grow from USD 4.06 billion in 2025 to USD 8.6 billion by 2035 at a 7.8% CAGR, this solution offers compelling advantages for moderate-to-severe disease applications, hospital-based specialty care, and diverse patient populations requiring proven biologic efficacy. Scaling market penetration and patient access requires coordinated action across healthcare policy, clinical guideline development, pharmaceutical manufacturers, dermatology specialists, and patient advocacy initiatives.

How Could Governments Spur Local Development and Adoption?

• Specialty Care Infrastructure: Include dermatology and rheumatology capacity building in healthcare development initiatives, providing targeted support for specialist training and supporting academic medical center development.
• Reimbursement Policy & Coverage: Implement comprehensive specialty biologic coverage in national health insurance programs, provide clear prior authorization criteria reducing administrative burden, and establish sustainable pricing frameworks balancing innovation incentives with affordability.
• Regulatory Framework Development: Create streamlined approval processes for biologic therapies and biosimilar products, establish clear pharmacovigilance requirements and post-marketing surveillance protocols, and develop international collaboration on safety monitoring.
• Patient Access Programs: Fund specialty pharmacy infrastructure and temperature-controlled distribution networks, invest in patient assistance programs reducing out-of-pocket costs, and explore risk-sharing arrangements with manufacturers.
• Research & Evidence Support: Establish registry programs for long-term safety and effectiveness monitoring, support health technology assessment and comparative effectiveness research, and create frameworks encouraging real-world evidence generation.

How Could Industry Bodies Support Market Development?

• Clinical Guidelines & Standards: Define evidence-based treatment algorithms for biologic therapy selection, establish standardized efficacy endpoints and safety monitoring protocols, and create educational resources supporting appropriate prescribing.
• Market Education & Awareness: Lead physician education on IL-23 pathway biology and clinical trial evidence, emphasizing proper patient selection criteria, injection technique training, and adverse event management.
• Quality Assurance Programs: Develop specialty pharmacy accreditation standards, cold chain management best practices, and patient counseling competency requirements ensuring safe medication handling.
• Professional Development: Run certification programs for dermatology nurses, specialty pharmacists, and patient educators on optimizing biologic therapy management and supporting patient adherence.

How Could Manufacturers and Healthcare Companies Strengthen the Ecosystem?

• Clinical Development Excellence: Develop comprehensive clinical trial programs demonstrating long-term efficacy and safety, conduct head-to-head comparative studies, and generate real-world evidence supporting value proposition.
• Patient Support Services: Provide comprehensive patient assistance programs including copay assistance, free drug programs for uninsured patients, and injection training support services.
• Healthcare Provider Partnerships: Offer technical education on mechanism of action and clinical data, develop treatment algorithms and patient selection tools, and provide reimbursement support services.
• Market Access Optimization: Build payer relationships demonstrating cost-effectiveness and budget impact, develop outcomes-based contracting arrangements, and create patient adherence programs improving treatment persistence.

How Could Healthcare Providers and Specialists Navigate the Market?

• Evidence-Based Prescribing: Incorporate validated treatment algorithms into clinical practice, with particular focus on patient phenotyping, disease severity assessment, and appropriate biologic selection for optimal outcomes.
• Patient Education Excellence: Establish comprehensive counseling on treatment expectations, self-injection techniques, and adverse event recognition through structured education programs.
• Multidisciplinary Care Integration: Implement collaborative care models combining dermatologists, rheumatologists, and mental health professionals addressing disease complexity and comorbidity management.
• Outcomes Monitoring Systems: Develop standardized response assessment using PASI scoring, patient-reported outcomes, and quality of life measures enabling treatment optimization and shared decision-making.

How Could Investors and Financial Enablers Unlock Value?

• Clinical Development Financing: Provide capital for pharmaceutical companies including Johnson & Johnson to fund Phase IV studies, label expansion trials, and comparative effectiveness research.
• Biosimilar Innovation Investment: Back companies developing IL-23 inhibitor biosimilars, specialized manufacturing capabilities, and emerging market distribution infrastructure reducing treatment costs.
• Market Access Technology: Finance companies developing patient support platforms, specialty pharmacy management systems, and reimbursement optimization technologies enhancing treatment access.
• Digital Health Integration: Support companies developing telemedicine dermatology platforms, patient adherence applications, and real-world evidence collection systems improving care delivery efficiency.

Key Players in the Tremfya Market

• Johnson & Johnson Services Inc.
• AbbVie Inc.
• Novartis AG
• Eli Lilly & Company
• UCB S.A.
• Amgen Inc.
• Bristol Myers Squibb
• Sun Pharma
• Biocon Biologics
• MorphoSys AG

Scope of the Report

Items	Values
Quantitative Units	USD 4.06 Billion
Application	Plaque Psoriasis, Psoriatic Arthritis, Others
Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regions Covered	Asia Pacific, Europe, North America, Latin America, Middle East & Africa
Country Covered	India, China, USA, Germany, Brazil, Japan, Saudi Arabia, and 40+ countries
Key Companies Profiled	Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, Eli Lilly & Company, UCB S.A., Amgen Inc., Bristol Myers Squibb, Sun Pharma, Biocon Biologics, MorphoSys AG
Additional Attributes	Dollar sales by application and distribution channel categories, regional adoption trends across Asia Pacific, Europe, and North America, competitive landscape with biopharmaceutical manufacturers and specialty pharmacy networks, product specifications and clinical efficacy profiles, integration with patient support programs and reimbursement systems, innovations in extended dosing regimens and subcutaneous formulations, and development of specialized applications with label expansion opportunities and comparative effectiveness validation.

Tremfya Market by Segments

• Application :

  • Plaque Psoriasis
    • Moderate-to-Severe Plaque Psoriasis
    • Chronic Plaque Psoriasis
    • Difficult-to-Treat Areas
  • Psoriatic Arthritis
  • Others

• Distribution Channel :

  • Hospital Pharmacies
    • Large Hospitals & Specialty Centers
    • Tertiary Care Hospitals
    • Government Hospitals
  • Retail Pharmacies
  • Online Pharmacies

• Region :

  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
    • Rest of Asia Pacific
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
    • Rest of Europe
  • North America
    • USA
    • Canada
    • Mexico
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Rest of Middle East & Africa